Leading Tech Giants Join Forces to Combat AI Election Threatby Lilu Anderson 13.02.2024Leading tech companies, including Google, Microsoft, and Meta, have signed an accord to combat deceptive AI-generated content ahead of crucial ...
Expro $210M Acquisition of Coretrax: Expanding Portfolioby Mark Eisenberg 13.02.2024Expro is set to acquire Coretrax for $210 million, expanding its well flow management capabilities. The deal will strengthen Expro's ...
MicroStrategy’s Bitcoin Bet: Smart Move or Risky Strategy?by John Darbie 13.02.2024MicroStrategy's embrace of Bitcoin as a key strategy for business growth positions it to take advantage of increasing demand for ...
Jefferies Raises Palo Alto Networks Price Target to $450by Terry Bingman 13.02.2024Jefferies raises price target for Palo Alto Networks to $450 due to positive evaluation of financial performance, projecting strong growth ...
Accuray’s Bold Move: A Game Changer in Oncology?by Mark Eisenberg 13.02.2024Accuray's strategic move into emerging markets, including China and India, is expected to bolster its growth outlook and attract investor ...
AI Impact on Jobs: Industry Contradictionsby Lilu Anderson 13.02.2024AI and the future of work brings both opportunities and challenges. While some industries may experience job gains and increased ...
ZoomInfo’s Stock Soars: Jefferies Ups Target to $24by Mark Eisenberg 13.02.2024ZoomInfo Technologies receives positive outlook adjustment from Jefferies, with raised price target and Buy rating. Strong financial position, impressive profit ...
TUI Surprises with €6 Million Quarterly Profitby Mark Eisenberg 13.02.2024TUI, the travel giant, has surprised investors by posting a quarterly profit of €6 million, surpassing expectations. The company's strong ...
Amazon Prime Lawsuit: Pay More for Ad-Free TV?by Lilu Anderson 13.02.2024Amazon is facing a lawsuit over imposing additional charges for ad-free streaming on Prime Video. The class action alleges breach ...
Eli Lilly’s Orfoscerinib: Jefferies Raises Price Targetby Mark Eisenberg 13.02.2024Investment banking firm Jefferies raises Eli Lilly's price target based on optimism over orfoscerinib, indicating strong confidence in its potential. ...